IP Library Patent Application 10573139
Patent Application
App. No. 10/573,139

Oral compositions and route of administration for the delivery of a thylakoid extract

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/573,139
Abstract

The present invention provides a new use for a thylakoid extract, that is for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, for its inocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of a thylakoid extract in the making of an oral composition for treating or preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formal of reactive oxygen species or inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Further is provided an oral composition comprising a thylakoid extract and a vehicle for oral ingestion or oral administration. An oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consists of water, physiological saline or propylene glycol is also provided as food or a food supplement, or as a pellet, or encapsulated granules or powder. The carrier may be present in an amount of 0.01% to 95% (w/w) of the total composition. The purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

Claims (11)

1 . A method for making an oral composition for treating or preventing a disease or disorder involving the formation of reactive oxygen species or inflammation, comprising combining purified thylakoids with a carrier, with the proviso that the carrier does not essentially consists of water, physiological saline or propylene glycol.

2 . A method for preventing oxidative damages to components of an oral composition, comprising adding purified thylakoids to said composition.

3 . The method according to claim 1 or 2 , wherein the oral composition is food or food supplement.

4 . A method for treating or preventing a disease or disorder involving the formation of reactive oxygen species or inflammation, in a subject, which comprises the step of orally administering an effective dose of purified thylakoids.

5 . An oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consists of water, physiological saline or propylene glycol.

6 . The oral composition of claim 5 , which is food or food supplement.

7 . The oral composition of claim 5 , which is a medication selected from the group consisting of a pellet, encapsulated granules and encapsulated powder.

8 . The oral composition of claim 5 , wherein the carrier is present in an amount of 0.01% to 95% (w/w).

9 . The method according to claim 1 or 2 , wherein the purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

10 . The method as defined in claim 4 , wherein the purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

11 . The composition according to any one of claims 5 to 8 , wherein the purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16154364 PREVIOUSLY RECORDED AT REEL: 048359 FRAME: 0174. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jun 28, 2021
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 057292/0433 →
SECURITY INTEREST Recorded Feb 18, 2019
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 048359/0174 →
SECURITY INTEREST Recorded Jul 9, 2014
From: PURGENESIS TECHNOLOGIES INC.
To: INVESTISSEMENT QUÉBEC
Reel/Frame 033283/0228 →
RE-RECORD TO CORRECT THE ADDRESS OF THE ASSIGNEE, PREVIOUSLY RECORDED ON REEL 017700 FRAME 0689. Recorded Jul 12, 2006
From: PURCELL, MARC; DROUIN, REJEAN
To: PURECELL TECHNOLOGIES INC.
Reel/Frame 017932/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2006
From: PURCELL, MARC; DROUIN, REJEAN
To: PURECELL TECHNOLOGIES INC.
Reel/Frame 017700/0689 →